"Norgine believes that there are attractive opportunities to develop innovative products which not only improve patient care but also can be proven to add economic value to the overall healthcare system."
"We are focused on identifying these opportunities and helping to bring them to market."
"Our vision is to be the 'go to' European specialist pharma company."
Achieve sustainable double digit growth
Norgine will achieve double digit growth by maximising the growth of its core brands - MOVICOL®, MOVIPREP®, XIFAXAN®, DANTRIUM® and ENDOCUFF VISION® as well as launching Norgine’s own products and those of its partners – PLENVU® and LYMPHOSEEK®
Maintain strong late stage pipeline
Norgine's priority is to acquire and develop new late stage products (phase III onwards) that will change medical care and add value to patients and healthcare systems.
Be a dynamic place to work
Norgine is fostering a dynamic environment which means employees are encouraged to challenge the status quo and make brave decisions.
Norgine infrastructure is flexible and agile enough to win product partnering opportunities and bring them to market quickly.